more

Novavax (NVAX)

(Delayed Data from NSDQ)

$4.29 USD

+0.20 (4.89%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $4.29 0.00 (0.00%) 4:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is Novavax (NVAX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research Published on January 11,2019

Is (NVAX) Outperforming Other Medical Stocks This Year?

NVAXPositive Net Change

Novavax (NVAX) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research Published on November 07,2018

Novavax (NVAX) delivered earnings and revenue surprises of 0.00% and -23.91%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

NVAXPositive Net Change

Novavax (NVAX) Gains As Market Dips: What You Should Know

by Zacks Equity Research Published on November 02,2018

Novavax (NVAX) closed at $1.92 in the latest trading session, marking a +1.05% move from the prior day.

NVAXPositive Net Change

What's in the Cards for Novavax (NVAX) This Earnings Season?

by Zacks Equity Research Published on October 31,2018

Investors are looking forward to Novavax's (NVAX) updates on its pipeline candidates when it reports third-quarter 2018 results.

biotechs

Will Novavax (NVAX) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research Published on October 30,2018

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NVAXPositive Net Change

Do Options Traders Know Something About Novavax (NVAX) Stock We Don't?

by Zacks Equity Research Published on October 04,2018

Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

NVAXPositive Net Change

Novavax (NVAX) Catches Eye: Stock Jumps 7.6%

by Zacks Equity Research Published on September 26,2018

Novavax (NVAX) shares rose nearly 8% in the last trading session, amid huge volumes.

Is the Options Market Predicting a Spike in Novavax (NVAX) Stock?

by Zacks Equity Research Published on August 27,2018

Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

NVAXPositive Net Change

Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on August 08,2018

Novavax (NVAX) delivered earnings and revenue surprises of 0.00% and 4.85%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

NVAXPositive Net Change

Has Novavax (NVAX) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research Published on April 26,2018

Is Novavax, Inc. (NVAX) Outperforming Other Medical Stocks This Year?

NVAXPositive Net Change

Pick 3 Biotech Money-Spinning Bets Amid Market Instability

by Debapriya Chakraborty Published on April 06,2018

The drugs/biotech sector has been down since the past month, reeling under broader market pressures. Only a few good stocks however, remain out of this rut.

Novavax (NVAX) in Focus: Stock Moves 8.3% Higher

by Zacks Equity Research Published on February 20,2018

The shares of Novavax (NVAX) rose over 8% yesterday.

3 Stocks Under $10 That Surged Today

by Benjamin Rains Published on January 18,2018

Here at Zacks, we encourage investors to follow our proven stock-picking system, which places a great deal of emphasis on earnings estimate revisions in order to find winning stocks. However, we also always seek to cover stocks, big and small, that are making noteworthy moves.